Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors.
We compared the expression of serologically detectable MHC and tumor-associated antigens on low and high metastasis variants of B16 melanoma tumor. Complement-dependent cytotoxicity, radioimmunobinding, and quantitative absorption assays showed that with respect to both types of antigens the low metastasis variant B16-F1 expressed a higher serologically detectable antigenicity than B16-F10, its high metastasis counterpart. A reverse situation existed in terms of in vivo immunogenicity of these metastasis variants. Sera from C57BL/6 mice bearing locally growing B16-F10 tumors had a higher binding activity to B16 cells than sera from B16-F1 bearers. Accordingly, in vivo propagating B16-F10 tumors had a higher content of tumor-associated Ig than B16-F1 tumors.
D000818:Animals; D000912:Antibodies, Neoplasm / Q000032:analysis*; D000951:Antigens, Neoplasm / Q000032:analysis*; D002462:Cell Membrane / Q000276:immunology; D008285:Major Histocompatibility Complex; D008545:Melanoma / Q000276:immunology*; D051379:Mice; D009374:Neoplasms, Experimental / Q000276:immunology
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm